Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.
Source: MedWire News - Lung Cancer - Category: Cancer & Oncology Source Type: news